Category: IHC-Antibodies

Name: TCL1 Antibody (Clone EP105)

Description and applications:T-cell leukemia/lymphoma protein 1A (TCL1) is a member of the TCL1 family and enhances the phosphorylation and activation of AKT1, AKT2 and AKT3. TCL1 promotes the nuclear translocation of AKT1 and enhances cell proliferation, stabilizes mitochondrial membrane potential and promotes cell
survival. The expression of TCL1 is restricted to lymphoid cells. It is expressed early in lymphocyte differentiation. Strong expression of TCL1 is fouma, follicular lymphoma, Burkitt lymphoma,diffuse large B-cell lymphoma (60%), and primary cutaneous B-cell lymphoma (55%). The expression of the TCL1 gene charactend in a subset of mantle zone B lymphocytes and is expressed to a lesser extent by follicle center cells. In B-cell neoplasia, TCL1 immunoreactivity is found in the majority of B-cell lymphomas including lymphoblastic lymphoma, chronic lymphocytic leukemia, mantle cell lymphorizes low-grade B-cell lymphomas.

Composition:Anti-human TCL1 rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.

Immunogen:Synthetic peptide corresponding to residues in human TCL1 protein.

Name: T-Box/TBX21 Antibody (Clone 4B10)

Description and applications: The T-bet transcription factor (more correctly called T-box TBX21 transcription factor), expressed in T cells, is one of the members of the T-box transcription factor family specific to Th1 cells. It is encoded by a gene located in the chromosomal region 17q21.32. The T-bet factor was originally isolated from nuclear extracts of resting and PMA/ionomycin-activated AE7 lymphoid cells; it is expressed in low levels in resting cells, and in increased levels in stimulated cells. T-bet regulates the secretion of IFN-γ by CD4 Th1 cells (although this mediator is also produced by NK cells and CD8+ cytotoxic T cells, in the latter case, independently of the presence of T-bet). Similarly, and under the right conditions, T-bet also converts effector Th2 cells into the opposing Th1 subset. In mice carrying T-bet gene deletions, lymphocytes differentiate into a predetermined stage of Th2 cells and are protected against lesions equivalent torheumatoid arthritis, which highlights the crucial role that this transcription factor plays in the induction of a Th1 response. For this reason, it is now known that an adequate level of T-bet activation contributes to a decrease of the excessive Th2 response found in bronchial hyperreactivity, oedema, and eosinophil granulocyte infiltration underlying bronchial asthma. In normal tissue, T-bet is expressed selectively and more intensely in Th1 cells, although at a lower level it is also found in NK cells and CD8+ cytotoxic T cells, and its expression level is increased in response to signals mediated by the T cell-specific receptor (TCR) and IL-12. In pathological situations, T-bet, in addition to being involved in the pathogenic mechanisms of some T cell lymphoproliferative processes, also regulates the response in some autoimmune diseases such as Crohn’s disease and type I diabetes mellitus. Finally, the presence of genetic variations in T-bet is associated with a greater susceptibility to bronchial asthma with sinonasal polyposis development and intolerance to aspirin. The implication of T-bet in the pathological development of B cells, as well as the development of some of the neoplastic lesions that are derived from them, has not yet been sufficiently analysed. In neoplasms, the T-bet transcription factor is expressed in all lymphomas originating from mature T cells, especially in peripheral T lymphomas, and is consistently negative in lymphomas derived from T cell precursors (lymphoblastic lymphomas). Likewise, most nasal NK/T lymphomas express nuclear T-bet regardless of the presence of Epstein-Barr virus or the presence of TCR receptor clonal rearrangement. Among B cell-derived neoplasms that most frequently express T-bet are marginal zone lymphomas, both extranodal and splenic, B lymphoblastic leukaemia, and hairy-cell leukaemia, in which T-bet positivity, along with TRAP, DBA.44, CD123, and Annexin-1 positivity, confirm diagnosis. Moreover, this antibody against T-bet has the advantage of being one of the few antibodies that work consistently in spine biopsies with hairy-cell leukaemia infiltration. Other lymphoproliferative lesions that may occasionally express T-bet are B cell chronic lymphocytic leukaemia, diffuse large B cell lymphoma, and classical Hodgkin lymphoma. Likewise, positivity has been described in some adenocarcinomas. In the differential diagnosis between lymphocytic colitis and coeliac disease, predominance of T-betpositive T cells, both in the epithelium and in the lamina propria, supports the latter diagnosis, while positive cells for both T-bet and GATA3 are more characteristic of lymphocytic colitis.

Composition: Anti-human T-Box TBX21 mouse monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.

Immunogen:Recombinant mouse T-bet protein.

Name:Synaptophysin Antibody (Clone EP158)

Description and applications: Synaptophysin is a major integral transmembrane glycoprotein of synaptic vesicles with four transmembrane domains. This protein is present in almost all neurons and neuroendocrine cells throughout the body. An antibody to Synaptophysin is useful for the identification of tumors with neural and
neuroendocrine differentiation. In well-differentiated tumors containing neurons (gangliocytoma, ganglioglioma, neurocytoma, ganglioneuroblastoma) synaptophysin is consistently expressed. Primitive neuroectodermal tumors (PNET) (cerebral PNET, medulloblastoma, neuroblastoma) show less intensity and variable reactivity.

 Composition: anti-human Synaptophysin rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.

Immunogen: A synthetic peptide corresponding to residues on the C-terminus (cytoplasmic domain) of human Synaptophysin protein.

Name: SOX-2 Antibody (Clone SP76)

Description and applications: Sex determining region Y-box 2 (SOX-2) is a stem cell marker and a transcription factor expressed in basal cells of the prostate, myoepithelial cells of the breast, squamous epithelium, and fetal neural cells. Recent studies show that SOX-2 is highly expressed in some human cancers such as prostate, lung, breast, and ovarian cancers. SOX2 is a sensitive marker of
embryonal carcinoma.

Composition: Anti-human SOX-2 rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.

Immunogen: Synthetic peptide corresponding to Nterminus of human SOX-2 protein.

Name: CD8 Antibody (Clone SP16)

Description and applications: CD8 molecule consists of two chains, termed α and β chain, which are expressed as a disulphide-linked α/β heterdimer or as an α/α homodimer on T cell subset, thymocytes and NK cells. The majority of CD8+ T cells express CD8 as α/β heterdimer. CD8 functions as a co-receptor in concert with TCR for binding the MHC class I/peptide complex. The HIV-2 envelope glycoprotein binds CD8 α chain (but not β chain). Along with other markers of T cells, CD8 it is used to establish diagnostic of T cell leukemias and lymphomas. The antibody is useful to ensure the origin of the lymphoid infiltrates present in biopsies and to distinguish reactive and neoplastic T cells.

Composition: anti-human CD8 rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.

Immunogen: Synthetic peptide corresponding to C-terminus of alpha chain of the human CD8 molecule.

Name: CD79a Antibody (Clone SP18)

Description and applications: A disulphide-linked heterodimer, consisting of CD79a/mb-1 and CD79b/B29 polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells to constitute the B cell Ag receptor. CD79a first appears at pre B cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is an excellent marker of B cells and tumors derived therefrom, particularly useful for identifying infiltration by pre-B lymphomas and acute leukemias with intense plasmacytoid differentiation. T cell lymphomas and myeloid malignancies are consistently negative.

Composition: anti-human CD79a rabbit monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.

Immunogen: Synthetic peptide derived from N-terminus region of human CD79a protein.

Name: CD33 Monoclonal Antibody (Clone PWS44)

Description and applications: Clone PWS44 detects the CD33 antigen on the membrane and in the cytoplasm of cells of myelomonocytic lineages. In normal bone marrow trephine biopsies, clone PWS44 stains myeloid and myelomonocytic hemopoiesis and mature macrophages; cells of the erythroid and megakaryocytic series are negative. Some reactivity was observed in cytotrophoblasts and syncytiotrophoblasts of placenta. Except for dendritic cells and infiltrating macrophages, no staining was observed in other normal tissues evaluated. Clone PWS44 stained acute myeloid leukemias, chronic myeloid leukemia, granulocytic sarcomas and cases of myeloid dysplasia and myeloproliferative diseases. PWS44 stained cases of non-lymphoid tumours. In the lymphoid neoplasms tested CD33 staining was observed in precursor B-lymphoblastic leukemias, precursor T-lymphoblastic leukemias, classical Hodgkin’s lymphomas, Burkitt lymphomas, plasma cell neoplasms, hematodermic lymphoid neoplasms, anaplastic large cell lymphoma, lymphoplasmacytic lymphoma.

Composition: anti-human CD33 mouse monoclonal antibody purified from tissue culture supernatant. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.

Immunogen: Prokaryotic recombinant protein corresponding to a region of the C2 domain of the human CD33 molecule.

Name: Mammaglobin Antibodies (Clones 304-1A5 & 31A5)

Description and applications: Mamoglobina is a 10 kDa glycoprotein associated to the breast and relacionada with the family of secretoglobinas which include uteroglobin and lipophilin. Mammaglobin is encoded by the gene MGB1 located on chromosome 11q12.3-q13. This chromosome is frequently amplified in breast carcinomas. As compared to normal breast more than 23% of primary breast carcinomas and 62% the metastases overexpress mammaglobin. Overexpression does not seem to be related to histology, hormone receptor expression, grade or tumor stage. Other tumors with focal or diffuse mammaglobin expression are endometrioid adenocarcinoma, cervical adenocarcinoma, salivary gland tumors, sweat gland tumors and some melanomas. Head and neck, thyroid, lung (adenocarcinoma, squamous), stomach, colon, pancreatic and ovarian tumors do not express mammaglobin. Compared to GCDFP-15, Mammaglobin has demonstrated higher sensitivity for identifying primary and metastatic breast tumors.

Composition: cocktail of anti-Mammaglobin antibodies obtained from supernatant culture and prediluted in a tris buffered solution pH 7.4 containing 0.375mM sodium azide solution as bacteriostatic and bactericidal.

Name: CD123 (Interleukin-3 Receptor Alpha Chain) Antibody (Clone 7G3)

Description and applications: The 7G3 monoclonal antibody specifically reacts with human CD123, the 70 kDa IL-3 Receptor α (IL-3Rα) chain. CD123 associates with CD131, the 120-140 kDa Common β chain to form the IL-3 Receptor Complex. CD131 is shared with the receptors for interleukins IL-5 and GM-CSF. IL-3Rα is expressed on hematopoietic progenitors and plays an important role in hematopoietic progenitor cell growth and differentiation. It is also expressed by mast cells, macrophages and a CD5+ B cell subset. This antibody has been reported to block the binding of 125I-IL-3 to high and low affinity IL-3 receptors. In functional experiments, this antibody was found to inhibit acute myeloid leukemia cell proliferation, basophil histamine release, endothelial cell-mediated IL-8 secretion, and neutrophil transmigration.The antibody is useful in paraffin sections to identify plasmacytoid dendritic cells, a distinct lineage of dendritic cells which are considered to gives rise to the blastic plasmacytoid dendritic cell neoplasia (CD4 + / CD56 + / CD123 +) and acute leukemia of ambiguous lineage (CD4 + / CD56- / CD123 +). Plasmacytoid dendritic cells (CD123 +) can be found in clumps in ocational cases os myeloid sarcoma with inv (16) and in chronic myelomonocytic leukemia.

Composition: anti-human CD123 mouse monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.